ASCLF (Ascletis Pharma) Change In Receivables : $0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Ascletis Pharma Change In Receivables?

Ascletis Pharma's change in receivables for the quarter that ended in Dec. 2024 was $0.00 Mil. It means Ascletis Pharma's Accounts Receivable stayed the same from Jun. 2024 to Dec. 2024 .

Ascletis Pharma's change in receivables for the fiscal year that ended in Dec. 2024 was $0.73 Mil. It means Ascletis Pharma's Accounts Receivable declined by $0.73 Mil from Dec. 2023 to Dec. 2024 .

Ascletis Pharma's Accounts Receivable for the quarter that ended in Dec. 2024 was $0.02 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Ascletis Pharma's Days Sales Outstanding for the six months ended in Dec. 2024 was 21.78.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Ascletis Pharma's liquidation value for the six months ended in Dec. 2024 was $246.05 Mil.

Ascletis Pharma Change In Receivables Historical Data

The historical data trend for Ascletis Pharma's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascletis Pharma Change In Receivables Chart

Ascletis Pharma Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Receivables

Get a 7-Day Free Trial

6.57

-4.24

4.27

2.58

0.73

Ascletis Pharma Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Change In Receivables	Get a 7-Day Free Trial												4.80	-	-	-	-

Ascletis Pharma Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.00 Mil.

Ascletis Pharma (OTCPK:ASCLF) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Ascletis Pharma's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.021	/	0.176	*	91
=	21.78

2. In Ben Graham's calculation of liquidation value, Ascletis Pharma's accounts receivable are only considered to be worth 75% of book value:

Ascletis Pharma's liquidation value for the quarter that ended in Dec. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	267.492	-	21.758	+	0.75 * 0.021	+	0.5 * 0.601
=	246.05

Ascletis Pharma Change In Receivables Related Terms

Thank you for viewing the detailed overview of Ascletis Pharma's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Ascletis Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascletis Pharma Inc (OTCPK:ASCLF) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

01672:Hong Kong 2VJ:Germany

Address

198 Qidi Road, 12th Floor, Building D, HIPARK, Xiaoshan District, Zhejiang Province, Hangzhou, CHN, 311200

Website

https://www.ascletis.com

Ascletis Pharma Inc is an investment holding company. Along with its subsidiaries, it is engaged in the research and development, production, marketing, and sale of pharmaceutical products. It has three marketed products, i.e. Ritonavir tablets, GANOVO, and ASCLEVIR. It also has other drug candidates in its pipeline in their different stages of development such as ASC22, ASC10, ASC11, and ASC40 among others. Geographically, it operates in Mainland China and other countries.